TAO Synergies (TAOX) Shares Outstanding (2019 - 2026)
TAO Synergies' (TAOX) quarterly Shares Outstanding (Entity) came in at $7.5 million in Q2 2026, up 377.45% on a YoY basis from $1.6 million in Q2 2025, and little changed quarter-over-quarter from $7.5 million in Q1 2026.
Analysis
TAO Synergies (TAOX) Shares Outstanding (2019 - 2026) Analysis & Trends
TAO Synergies (TAOX) has reported Shares Outstanding (Entity) for 8 consecutive years, with $7.5 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Shares Outstanding (Entity) rose 377.45% year-over-year to $7.5 million; the trailing twelve-month figure through Jun 2026 stood at $7.5 million (up 377.45% YoY), and the FY2025 full-year result was $3.3 million, up 143.17% from the prior year.
- Shares Outstanding (Entity) steadied at $7.5 million in Q2 2026 per TAOX's latest filing, from $7.5 million in the prior quarter.
- Across five years, Shares Outstanding (Entity) topped out at $11.7 million in Q4 2023 and bottomed at $1.1 million in Q1 2024.
- Historically, Shares Outstanding (Entity) has averaged $5.2 million across 5 years, with a median of $6.8 million in 2022.
- The sharpest annual moves came in 2024 and 2026: Shares Outstanding (Entity) plunged 88.35% in 2024, then surged 437.62% in 2026.
- Over 5 years, Shares Outstanding (Entity) stood at $7.3 million in 2022, then surged by 60.34% to $11.7 million in 2023, then slumped by 88.35% to $1.4 million in 2024, then jumped by 143.17% to $3.3 million in 2025, then jumped by 126.44% to $7.5 million in 2026.
- According to Business Quant data, Shares Outstanding (Entity) over the past three periods registered $7.5 million, $7.5 million, and $3.3 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 212.35 Bn | 198.36 Bn | 7.24 Bn | 540.00 Mn |
| 2 | Gilead Sciences | 181.19 Bn | 178.01 Bn | 6.22 Bn | 1.24 Bn |
| 3 | Vertex Pharmaceuticals | 132.48 Bn | 124.62 Bn | 2.84 Bn | 253.70 Mn |
| 4 | Regeneron Pharmaceuticals | 82.59 Bn | 74.60 Bn | 3.93 Bn | 102.80 Mn |
| 5 | Argenx Se | 61.45 Bn | 56.27 Bn | 1.37 Bn | 61.30 Mn |
| 6 | Moderna | 54.89 Bn | 49.75 Bn | 52.00 Mn | 398.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.21 Bn | 30.90 Bn | 992.69 Mn | 133.61 Mn |
| 8 | Biogen | 31.38 Bn | 30.10 Bn | 1.96 Bn | 147.70 Mn |
| 9 | Roivant Sciences | 29.81 Bn | 29.81 Bn | 1.16 Mn | 720.78 Mn |
| 10 | TAO Synergies | 30.41 Mn | 30.41 Mn | - | 7.47 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 7.47 Mn |
| Mar 31, 2026 | 7.48 Mn |
| Dec 31, 2025 | 3.30 Mn |
| Sep 30, 2025 | 2.55 Mn |
| Jun 30, 2025 | 1.57 Mn |
| Mar 31, 2025 | 1.39 Mn |
| Dec 31, 2024 | 1.23 Mn |
| Sep 30, 2024 | 1.32 Mn |
| Jun 30, 2024 | 1.21 Mn |
| Mar 31, 2024 | 1.04 Mn |
| Dec 31, 2023 | 11.65 Mn |
| Sep 30, 2023 | 10.70 Mn |
| Jun 30, 2023 | 7.36 Mn |
| Mar 31, 2023 | 7.50 Mn |
| Dec 31, 2022 | 6.99 Mn |
| Sep 30, 2022 | 6.99 Mn |
| Jun 30, 2022 | 6.96 Mn |
| Mar 31, 2022 | 6.94 Mn |
| Dec 31, 2021 | 5.02 Mn |
| Sep 30, 2021 | 6.20 Mn |